<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5450060.txt
<DESCRIPTION>PFIZER INC. 8-K
<TEXT>
                                 UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of report (Date of earliest event reported): July 18, 2007


                                   PFIZER INC.
             (Exact name of registrant as specified in its charter)

           Delaware                1-3619                13-5315170
      (State or other         (Commission File        (I.R.S. Employer
       jurisdiction of           (Number)           Identification No.)
       incorporation)


            235 East 42nd Street                            10017
            New York, New York                           (Zip Code)
                    (Address of principal executive offices)


               Registrant's telephone number, including area code:
                                 (212) 573-2323

                                 Not Applicable
          (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2 (b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))

<PAGE>

Item 2.02 Results of Operations and Financial Condition

On July 18, 2007, Pfizer Inc. ("Pfizer") issued a press release announcing its
financial results for the second quarter of 2007. The information contained in
the press release is deemed to be "filed" under the Securities Exchange Act of
1934 as Exhibit 99 to this report, and such press release is incorporated herein
by reference.


Item 9.01 Financial Statements and Exhibits

(d)  Exhibits

Exhibit 99  -  Press Release of Pfizer Inc. dated July 18, 2007, reporting
               Pfizer's financial results for the second quarter of 2007.
               Exhibit 99 is deemed to be "filed" under the Securities Exchange
               Act of 1934 in this Current Report on Form 8-K.

<PAGE>

                                  SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.

                   PFIZER INC.

                   By: /s/ Margaret M. Foran
                   ----------------------------
                   Margaret M. Foran
                   Title: Senior Vice President-Corporate Governance,
                   Associate General Counsel and Corporate Secretary

Dated: July 18, 2007


<PAGE>

                                  EXHIBIT INDEX

Exhibit No.    Description

99             Press Release of Pfizer Inc. dated
               July 18, 2007, reporting Pfizer's financial
               results for the second quarter of 2007.

</TEXT>
</DOCUMENT>